{"id":"NCT01291511","sponsor":"Vanda Pharmaceuticals","briefTitle":"Relapse Prevention Study in Patients With Schizophrenia","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Dose Iloperidone or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weeks of Open-label Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2014-03","completion":"2015-03","firstPosted":"2011-02-08","resultsPosted":"2023-07-17","lastUpdate":"2023-07-17"},"enrollment":635,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Iloperidone","otherNames":["FanaptÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Iloperidone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia","primaryOutcome":{"measure":"Time to Relapse or Impending Relapse","timeFrame":"Up to 26 weeks post-randomization","effectByArm":[{"arm":"Iloperidone","deltaMin":null,"sd":null},{"arm":"Placebo","deltaMin":99,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":16},"locations":{"siteCount":63,"countries":["United States","India","Ukraine"]},"refs":{"pmids":["27379654"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":629},"commonTop":["Dizziness","Somnolence","Headache","Insomnia","Dry mouth"]}}